Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
NEW YORK Publicis Groupe’s Saatchi & Saatchi, already eliminated in the review for creative chores on Tylenol’s estimated $115 million account, is losing ad duties on the three other Johnson & Johnson brands it handles: Pepcid, Mylanta and St. Joseph aspirin, an agency representative confirmed. Spending on those brands is estimated at $75 million.
It’s unclear where the brands will land. But under one scenario, they could shift wholesale to another roster shop, such as Interpublic Group’s Alchemy in New York, sources said.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in